Skip to main content

Rocaltrol Disease Interactions

There are 6 disease interactions with Rocaltrol (calcitriol).

Major

Vitamin D analogs (applies to Rocaltrol) arrhythmia

Major Potential Hazard, High plausibility. Applicable conditions: Arrhythmias

Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides. Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias. Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.

References

  1. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma PROD (2001):
  2. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories PROD (2001):
  3. "Product Information. Calderol (calcifediol)." Organon PROD (2001):
Major

Vitamin D analogs (applies to Rocaltrol) electrolyte imbalance

Major Potential Hazard, High plausibility. Applicable conditions: Phosphate Imbalance

Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or renal systems or other soft tissue calcifications. A solubility product (Serum Calcium X Phosphate) should not exceed 70. Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.

References

  1. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma PROD (2001):
  2. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories PROD (2001):
  3. "Product Information. Calderol (calcifediol)." Organon PROD (2001):
  4. "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical PROD (2001):
View all 4 references
Major

Vitamin D analogs (applies to Rocaltrol) hypercalcemia

Major Potential Hazard, Moderate plausibility. Applicable conditions: Malabsorption Syndrome

Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.

References

  1. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories PROD (2001):
  2. "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical PROD (2001):
  3. "Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc (2002):
  4. "Product Information. Drisdol (ergocalciferol)." sanofi-aventis (2016):
View all 4 references
Major

Vitamin D analogs (applies to Rocaltrol) renal dysfunction

Major Potential Hazard, High plausibility.

Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation. Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.

References

  1. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma PROD (2001):
  2. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories PROD (2001):
  3. "Product Information. Calderol (calcifediol)." Organon PROD (2001):
Moderate

Calcitriol (applies to Rocaltrol) dialysis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Calcitriol increases inorganic phosphate levels in serum and caution should be used in patients with renal impairment to maintain adequate phosphorus levels and avoid ectopic calcification. A non-aluminum phosphate-binding compound and a low phosphate diet should be used to control serum phosphorus levels in patients undergoing dialysis.

References

  1. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories PROD (2001):
Moderate

Vitamin D analogs (applies to Rocaltrol) hepatobiliary dysfunction

Moderate Potential Hazard, High plausibility. Applicable conditions: Biliary Obstruction, Liver Disease

Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs. Metabolites of vitamin D analogs are primarily excreted in bile and feces. Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation. Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.

References

  1. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma PROD (2001):
  2. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories PROD (2001):
  3. "Product Information. Calderol (calcifediol)." Organon PROD (2001):

Rocaltrol drug interactions

There are 70 drug interactions with Rocaltrol (calcitriol).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer